[新辅助化疗期间CA125半衰期与晚期上皮性卵巢癌患者最佳手术率及预后的关系]
[Relationship between CA125 half life during neoadjuvant chemotherapy and the optimal operation rate and prognosis in patients with advanced epithelial ovarian carcinoma].
作者信息
Xi Xiao-wei, Wan Xiao-ping, Li Shuang-di, Sun Ting-wei, Zhu Ya-ping
机构信息
Department of Obstetrics and Gynecology, Shanghai First People's Hospital, Shanghai Jiaotong University, Shanghai 200080, China.
出版信息
Zhonghua Fu Chan Ke Za Zhi. 2006 Feb;41(2):91-4.
OBJECTIVE
To investigate the relationship between the serum half life of CA(125) and the optimal operation rate and prognosis in patients with advanced epithelial ovarian carcinoma treated with neoadjuvant chemotherapy.
METHODS
Clinical data of 39 patients who had undergone neoadjuvant chemotherapy were analyzed retrospectively. Patients were divided into two groups according to the serum half-life of CA(125), and the optimal operation rate and prognosis were compared.
RESULTS
The optimal operation rate in patients with serum half-life >or= 20 days was significantly lower than that in patients with serum half-life < 20 days (29% vs 80%, P < 0.01). Cumulative survival was higher in patients with serum half-life < 20 days (P < 0.01). Serum half-life of CA(125) and tumor residual after operation were independent prognostic factors by COX model analysis.
CONCLUSION
Serum half-life of CA(125) may indicate optimal debulking operation, and it is an independent prognostic factor in ovarian carcinoma patients treated with neoadjuvant chemotherapy.
目的
探讨晚期上皮性卵巢癌患者接受新辅助化疗后血清CA(125)半衰期与最佳手术率及预后的关系。
方法
回顾性分析39例接受新辅助化疗患者的临床资料。根据血清CA(125)半衰期将患者分为两组，比较最佳手术率及预后。
结果
血清半衰期≥20天患者的最佳手术率显著低于血清半衰期<20天的患者（29%对80%，P<0.01）。血清半衰期<20天患者的累积生存率更高（P<0.01）。COX模型分析显示，血清CA(125)半衰期及术后肿瘤残留是独立的预后因素。
结论
血清CA(125)半衰期可能提示最佳肿瘤细胞减灭术，是接受新辅助化疗的卵巢癌患者的独立预后因素。
Zotero 插件